Aubagne, April 7, 2015 - At today's Annual General Shareholders' Meeting (AGM) of Sartorius Stedim Biotech S.A. in Aubagne, France, shareholders approved the Board of Directors' proposals by a large majority.

The AGM thus passed the resolution to pay dividends of €1.30 net per share for fiscal 2014, up from €1.20 a year earlier. The total profit distributed will therefore rise from €18.4 million to €20.0 million.

The AGM elected new non-executive members to the Board of Directors: Anne Marie Graffin, Managing Director of SMAG Consulting SARL, and Susan Dexter, Principal Consultant of the Latham Biopharm Group. As a result, the number of Board members has increased from eight to ten. In addition, Oscar-Werner Reif's term on the Board was renewed following his initial appointment in 2009. As Executive Vice President, he also manages the Group's global Research & Development unit.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

distributed by